UCSF home page About UCSF UCSF Medical Center
UCSF home page | About UCSF | UCSF Medical Center

Skip to TransPortal content

Decrease the text sizeRestore original text sizeIncrease the text size Enlarge Text
Click to increase the text size. Restore Text
Click to restore original text size. Reduce Text
Click to decrease the text size.
Transporter Database banner  
Decrease the text size | Restore text size | Increase the text size
 Text Sizer image
Home About and More Information Transporter Data Index
Search:  
 

SLC47A1

Synonyms: FLJ10847, MATE1, MGC64822

Entrez Gene Link

Expression Data
Substrate Information
Inhibitor Information
Clinical Drug-drug Interactions

Orthologs in other species

rat Slc47a1

Expression Data

Expression data for other tissues could be found in http://pharmacogenetics.ucsf.edu/gtex/index.html

Asterisk indicates important transporters in the organ as identified in the organ diagram.

Organ Source Relative Expression
Kidney* Mean across all PMT Samples 10.743
Liver* Mean across all PMT Samples 18.098
Note that relative expression values should only be compared between entries of the same source.

Back to top

In Vitro Substrates

Substrate Km (μM) Cell System Reference
Acyclovir 2640 HEK293-MATE1 Tanihara, 2007
Amphetamine 14 HEK293-MATE1 Wagner, 2017
Butylscopolamine 28.9 HEK293-MATE1 Chen, 2017
Cimetidine2,4 170 HEK293-MATE1 Tanihara, 2007
Estrone sulfate 470 HEK293-MATE1 Tanihara, 2007
Ganciclovir 5120 HEK293-MATE1 Tanihara, 2007
Guanidine 2100 HEK293-MATE1 Tanihara, 2007
Ipratropium 44.8 HEK293-MATE1 Chen, 2017
Metformin1,3 780 HEK293-MATE1 Tanihara, 2007
Metformin1,3 227 HEK293-MATE1 Chen, 2009
Metformin1,3 202 HeLa-MATE1 Meyer, 2010
Methamphetamine 21 HEK293-MATE1 Wagner, 2017
N-methylpyridinium 16 HEK293-MATE1 Otsuka, 2005
N-methylpyridinium 100 HEK293-MATE1 Tanihara, 2007
Paraquat 212 HEK293 cells Chen, 2007
Paraquat 169 HEK293-MATE1 Chen, 2009
Procainamide 1230 HEK293-MATE1 Tanihara, 2007
Sulpiride 14.5 MDCK-MATE1 Li, 2017
Tetraethylammonium1 220 HEK293-MATE1 Otsuka, 2005
Tetraethylammonium1 380 HEK293-MATE1 Xie, 2007
Topotecan 70 HEK293-MATE1 Tanihara, 2007
Trospium 15.4 HEK293-MATE1 Chen, 2017

ND = not determined
1 denotes drugs that can potentially be used as in vitro substrates for studies of the transporter as defined by the FDA as of March 2022
2 denotes drugs that can potentially be used as in vitro inhibitors for studies of the transporter as defined by the FDA as of March 2022
3 denotes drugs that can potentially be used as clinical substrates for studies of the transporter as defined by the FDA as of March 2022
4 denotes drugs that can potentially be used as clinical inhibitors for studies of the transporter as defined by the FDA as of March 2022


Back to top

In Vitro Inhibitors

Inhibitor IC50 (μM) Ki (μM) Substrate used Cell System Reference
Abemaciclib 0.52 Metformin1,3 HEK293-MATE1 Chappell, 2019
Agmatine 54 1-methyl-4-phenylpyridinium (MPP+) CHO-MATE1 Astorga, 2012
Allethrin 50.2 Tetraethylammonium1 HEK293 cells Chedik, 2017
Amantadine 7.5 1-methyl-4-phenylpyridinium (MPP+) CHO-MATE1 Astorga, 2012
Amantadine 37.8 4-(4-dimethylamino)styryl-N-methylpyridinium (ASP+) HEK293-MATE1 Wittwer, 2013
Amantadine 111.8 Tetraethylammonium1 HEK293-MATE1 Tsuda, 2009
Amiloride 2.4 1-methyl-4-phenylpyridinium (MPP+) CHO-MATE1 Astorga, 2012
Amphetamine 94 Metformin1,3 HEK293-MATE1 Wagner, 2017
Aripiprazole 130 4-(4-dimethylamino)styryl-N-methylpyridinium (ASP+) HEK293-MATE1 Wittwer, 2013
Astemizole 26.4 4-(4-dimethylamino)styryl-N-methylpyridinium (ASP+) HEK293-MATE1 Wittwer, 2013
Atropine 6 1-methyl-4-phenylpyridinium (MPP+) CHO-MATE1 Astorga, 2012
Bisphenol A 73.5 Tetraethylammonium1 HEK293 cells Bruyere, 2017
Bithionol 5.2 4-(4-dimethylamino)styryl-N-methylpyridinium (ASP+) HEK293-MATE1 Wittwer, 2013
Buspirone 1.7 4-(4-dimethylamino)styryl-N-methylpyridinium (ASP+) HEK293-MATE1 Wittwer, 2013
Butylscopolamine 8.2 1-methyl-4-phenylpyridinium (MPP+) HEK293-MATE1 Chen, 2017
Camostat 2.9 4-(4-dimethylamino)styryl-N-methylpyridinium (ASP+) HEK293-MATE1 Wittwer, 2013
Carvedilol 92.4 4-(4-dimethylamino)styryl-N-methylpyridinium (ASP+) HEK293-MATE1 Wittwer, 2013
Cetirizine 371.2 Tetraethylammonium1 HEK293-MATE1 Tsuda, 2009
Chlorhexidine 0.7 4-(4-dimethylamino)styryl-N-methylpyridinium (ASP+) HEK293-MATE1 Wittwer, 2013
Chloroquine 1.5 Ipratropium HEK293-MATE1 Chen, 2017
Chloroquine 2.5 Metformin1,3 HEK293-MATE1 Muller, 2011
Chlorpheniramine 87.6 Tetraethylammonium1 HEK293-MATE1 Tsuda, 2009
Cimetidine2,4 5.7 4-(4-dimethylamino)styryl-N-methylpyridinium (ASP+) HEK293-MATE1 Kido, 2011
Cimetidine2,4 1.2 4-(4-dimethylamino)styryl-N-methylpyridinium (ASP+) HEK293-MATE1 Wittwer, 2013
Cimetidine2,4 3.8 Metformin1,3 HEK293-MATE1 Ito, 2012
Cimetidine2,4 2.56 Metformin1,3 HEK293-MATE1 Lechner, 2016
Cimetidine2,4 1.1 Tetraethylammonium1 HEK293-MATE1 Tsuda, 2009
Clonidine 8.09 1-methyl-4-phenylpyridinium (MPP+) CHO-MATE1 Astorga, 2012
Clonidine 33.3 4-(4-dimethylamino)styryl-N-methylpyridinium (ASP+) HEK293-MATE1 Wittwer, 2013
Cobicistat 4.4 1-methyl-4-phenylpyridinium (MPP+) HEK293-MATE1 Kikuchi, 2019
Cortisone 21.4 4-(4-dimethylamino)styryl-N-methylpyridinium (ASP+) HEK293-MATE1 Wittwer, 2013
Dabigatran 8.1 4-(4-dimethylamino)styryl-N-methylpyridinium (ASP+) HEK293-MATE1 Wittwer, 2013
Dasatinib 0.8 Metformin1,3 HEK293-MATE1 Minematsu, 2011
Desipramine 55.7 Tetraethylammonium1 HEK293-MATE1 Tsuda, 2009
Dihydroergotamine 2.8 4-(4-dimethylamino)styryl-N-methylpyridinium (ASP+) HEK293-MATE1 Wittwer, 2013
Diltiazem 12.5 Tetraethylammonium1 HEK293-MATE1 Tsuda, 2009
Diphenhydramine 87 Tetraethylammonium1 HEK293-MATE1 Tsuda, 2009
Dipyridamole 24 4-(4-dimethylamino)styryl-N-methylpyridinium (ASP+) HEK293-MATE1 Kido, 2011
Dipyridamole 26 4-(4-dimethylamino)styryl-N-methylpyridinium (ASP+) HEK293-MATE1 Kido, 2011
Disopyramide 66 4-(4-dimethylamino)styryl-N-methylpyridinium (ASP+) HEK293-MATE1 Kido, 2011
Disopyramide 83.8 Tetraethylammonium1 HEK293-MATE1 Tsuda, 2009
Dolutegravir4 4.7 Tetraethylammonium1 CHO-MATE1 Lepist, 2014
Domperidone 2.3 4-(4-dimethylamino)styryl-N-methylpyridinium (ASP+) HEK293-MATE1 Wittwer, 2013
Donepezil 0.78 Metformin1,3 CHO-MATE1 Martinez-Guerrero, 2016
DX-619 0.82 Creatinine HEK293-MATE1 Imamura, 2011
Epinastine 1.1 4-(4-dimethylamino)styryl-N-methylpyridinium (ASP+) HEK293-MATE1 Wittwer, 2013
Erlotinib 8 Metformin1,3 HEK293-MATE1 Minematsu, 2011
Esmolol 11 Metformin1,3 CHO-MATE1 Martinez-Guerrero, 2016
Ethinyl estradiol 21.1 4-(4-dimethylamino)styryl-N-methylpyridinium (ASP+) HEK293-MATE1 Wittwer, 2013
Famotidine 2.16 1-methyl-4-phenylpyridinium (MPP+) CHO-MATE1 Astorga, 2012
Famotidine 0.76 4-(4-dimethylamino)styryl-N-methylpyridinium (ASP+) HEK293-MATE1 Wittwer, 2013
Famotidine 0.6 Tetraethylammonium1 HEK293-MATE1 Tsuda, 2009
Gabexate 0.5 4-(4-dimethylamino)styryl-N-methylpyridinium (ASP+) HEK293-MATE1 Wittwer, 2013
Gefitinib 1.82 Metformin1,3 HEK293-MATE1 Minematsu, 2011
Granisetron 5 4-(4-dimethylamino)styryl-N-methylpyridinium (ASP+) HEK293-MATE1 Wittwer, 2013
Guanfacine 3.5 1-methyl-4-phenylpyridinium (MPP+) CHO-MATE1 Astorga, 2012
Homatropine 18.7 1-methyl-4-phenylpyridinium (MPP+) HEK293-MATE1 Chen, 2017
Imatinib 0.35 4-(4-dimethylamino)styryl-N-methylpyridinium (ASP+) HEK293-MATE1 Wittwer, 2013
Imatinib 0.04 Metformin1,3 MDCK2- MATE1 Wittwer, 2013
Imatinib 0.05 Metformin1,3 HEK293-MATE1 Wittwer, 2013
Imipramine 10 4-(4-dimethylamino)styryl-N-methylpyridinium (ASP+) HEK293-MATE1 Kido, 2011
Imipramine 42 Tetraethylammonium1 HEK293-MATE1 Tsuda, 2009
Imiquimod 14 1-methyl-4-phenylpyridinium (MPP+) CHO-MATE1 Astorga, 2012
Indinavir 7.8 4-(4-dimethylamino)styryl-N-methylpyridinium (ASP+) HEK293-MATE1 Wittwer, 2013
Indinavir 1.7 Metformin1,3 HEK293-MATE1 Wittwer, 2013
Indinavir 1.9 Metformin1,3 MDCK2- MATE1 Wittwer, 2013
Ipratropium 30.5 1-methyl-4-phenylpyridinium (MPP+) HEK293-MATE1 Chen, 2017
Irinotecan 7.9 4-(4-dimethylamino)styryl-N-methylpyridinium (ASP+) HEK293-MATE1 Wittwer, 2013
Irinotecan 2.1 Metformin1,3 HEK293-MATE1 Wittwer, 2013
Irinotecan 4.3 Metformin1,3 MDCK2- MATE1 Wittwer, 2013
Ketoconazole 1.33 1-methyl-4-phenylpyridinium (MPP+) CHO-MATE1 Astorga, 2012
Ketotifen 12.7 Metformin1,3 CHO-MATE1 Martinez-Guerrero, 2016
Levofloxacin 17.9 4-(4-dimethylamino)styryl-N-methylpyridinium (ASP+) HEK293-MATE1 Wittwer, 2013
Losartan 250 4-(4-dimethylamino)styryl-N-methylpyridinium (ASP+) HEK293-MATE1 Wittwer, 2013
Maraviroc 17.3 4-(4-dimethylamino)styryl-N-methylpyridinium (ASP+) HEK293-MATE1 Wittwer, 2013
Metamphetamine 107 Metformin1,3 HEK293-MATE1 Wagner, 2017
Metformin1,3 47 1-methyl-4-phenylpyridinium (MPP+) CHO-MATE1 Astorga, 2012
Metformin1,3 250 4-(4-dimethylamino)styryl-N-methylpyridinium (ASP+) HEK293-MATE1 Wittwer, 2013
Metformin1,3 666.9 Tetraethylammonium1 HEK293-MATE1 Tsuda, 2009
Methyl ergonovine 250 4-(4-dimethylamino)styryl-N-methylpyridinium (ASP+) HEK293-MATE1 Wittwer, 2013
Midodrine 109 1-methyl-4-phenylpyridinium (MPP+) CHO-MATE1 Astorga, 2012
Mitoxantrone 0.53 4-(4-dimethylamino)styryl-N-methylpyridinium (ASP+) HEK293-MATE1 Wittwer, 2013
Mitoxantrone 4.4 Metformin1,3 HeLa-MATE1 Meyer, 2010
Mitoxantrone 0.19 Metformin1,3 MDCK2- MATE1 Wittwer, 2013
Mitoxantrone 0.4 Metformin1,3 HEK293-MATE1 Wittwer, 2013
Mitoxantrone 5.2 Tetraethylammonium1 HeLa-MATE1 Meyer, 2010
N-butylpyridinium chloride (NBuPy-Cl) 8.5 1-methyl-4-phenylpyridinium (MPP+) CHO-MATE1 Cheng, 2011
Naloxone 24.1 1-methyl-4-phenylpyridinium (MPP+) CHO-MATE1 Astorga, 2012
Nialamide 212 1-methyl-4-phenylpyridinium (MPP+) CHO-MATE1 Astorga, 2012
Nicotine 167 1-methyl-4-phenylpyridinium (MPP+) CHO-MATE1 Astorga, 2012
Nifekalant 6.5 4-(4-dimethylamino)styryl-N-methylpyridinium (ASP+) HEK293-MATE1 Wittwer, 2013
Nifekalant 0.65 Metformin1,3 MDCK2- MATE1 Wittwer, 2013
Nifekalant 1.1 Metformin1,3 HEK293-MATE1 Wittwer, 2013
Noscapine 34.5 4-(4-dimethylamino)styryl-N-methylpyridinium (ASP+) HEK293-MATE1 Wittwer, 2013
Omeprazole 16.1 Metformin1,3 CHO-MATE1 Martinez-Guerrero, 2016
Ondansetron 0.15 4-(4-dimethylamino)styryl-N-methylpyridinium (ASP+) HEK293-MATE1 Kido, 2011
Ondansetron 0.16 4-(4-dimethylamino)styryl-N-methylpyridinium (ASP+) HEK293-MATE1 Wittwer, 2013
Ondansetron 0.01 Metformin1,3 MDCK2- MATE1 Wittwer, 2013
Ondansetron 0.03 Metformin1,3 HEK293-MATE1 Wittwer, 2013
Orphenadrine 65 4-(4-dimethylamino)styryl-N-methylpyridinium (ASP+) HEK293-MATE1 Kido, 2011
Pantoprazole 43.2 4-(4-dimethylamino)styryl-N-methylpyridinium (ASP+) HEK293-MATE1 Wittwer, 2013
Pantoprazole 2.8 Metformin1,3 MDCK2- MATE1 Wittwer, 2013
Pantoprazole 2.8 Metformin1,3 HEK293-MATE1 Wittwer, 2013
Pentamidine 2.7 4-(4-dimethylamino)styryl-N-methylpyridinium (ASP+) HEK293-MATE1 Wittwer, 2013
Pentamidine 0.41 Metformin1,3 MDCK2- MATE1 Wittwer, 2013
Pentamidine 2 Metformin1,3 HEK293-MATE1 Wittwer, 2013
Phentolamine 4.64 1-methyl-4-phenylpyridinium (MPP+) CHO-MATE1 Astorga, 2012
Pimozide >500 4-(4-dimethylamino)styryl-N-methylpyridinium (ASP+) HEK293-MATE1 Wittwer, 2013
Pramipexole 141.4 Tetraethylammonium1 HEK293-MATE1 Tsuda, 2009
Prazosin 1.6 4-(4-dimethylamino)styryl-N-methylpyridinium (ASP+) HEK293-MATE1 Wittwer, 2013
Procainamide 24 1-methyl-4-phenylpyridinium (MPP+) CHO-MATE1 Astorga, 2012
Procainamide 217 Tetraethylammonium1 HEK293-MATE1 Tsuda, 2009
Prochlorperazine 7.9 Metformin1,3 CHO-MATE1 Martinez-Guerrero, 2016
Proguanil 4.35 1-methyl-4-phenylpyridinium (MPP+) CHO-MATE1 Astorga, 2012
Propranolol 7.81 1-methyl-4-phenylpyridinium (MPP+) CHO-MATE1 Astorga, 2012
Pyrimethamine2 0.07 Ipratropium HEK293-MATE1 Chen, 2017
Quinidine 1.57 1-methyl-4-phenylpyridinium (MPP+) CHO-MATE1 Astorga, 2012
Quinidine 11.2 4-(4-dimethylamino)styryl-N-methylpyridinium (ASP+) HEK293-MATE1 Wittwer, 2013
Quinidine 29.2 Tetraethylammonium1 HEK293-MATE1 Tsuda, 2009
Quinine 2 1-methyl-4-phenylpyridinium (MPP+) CHO-MATE1 Astorga, 2012
Ranitidine 5.4 1-methyl-4-phenylpyridinium (MPP+) CHO-MATE1 Astorga, 2012
Ranitidine 8.3 4-(4-dimethylamino)styryl-N-methylpyridinium (ASP+) HEK293-MATE1 Wittwer, 2013
Ranitidine 18.9 Metformin1,3 HeLa-MATE1 Meyer, 2010
Ranitidine 25.4 Tetraethylammonium1 HEK293-MATE1 Tsuda, 2009
Ranitidine 17.5 Tetraethylammonium1 HeLa-MATE1 Meyer, 2010
Rapamycin 3.27 Metformin1,3 HeLa-MATE1 Meyer, 2010
Rapamycin 3.51 Tetraethylammonium1 HeLa-MATE1 Meyer, 2010
Rimantadine 7.3 4-(4-dimethylamino)styryl-N-methylpyridinium (ASP+) HEK293-MATE1 Wittwer, 2013
Risperidone 1.6 4-(4-dimethylamino)styryl-N-methylpyridinium (ASP+) HEK293-MATE1 Wittwer, 2013
Ritonavir 4.4 4-(4-dimethylamino)styryl-N-methylpyridinium (ASP+) HEK293-MATE1 Wittwer, 2013
Ritonavir 15.4 Metformin1,3 HeLa-MATE1 Meyer, 2010
Ritonavir 0.08 Metformin1,3 HEK293-MATE1 Wittwer, 2013
Ritonavir 2.1 Metformin1,3 MDCK2- MATE1 Wittwer, 2013
Ritonavir 13.9 Tetraethylammonium1 HeLa-MATE1 Meyer, 2010
Scopolamine 47.6 1-methyl-4-phenylpyridinium (MPP+) CHO-MATE1 Astorga, 2012
Scopolamine 119.2 1-methyl-4-phenylpyridinium (MPP+) HEK293-MATE1 Chen, 2017
Spironolactone 18.6 4-(4-dimethylamino)styryl-N-methylpyridinium (ASP+) HEK293-MATE1 Wittwer, 2013
Sumatriptan 6.7 4-(4-dimethylamino)styryl-N-methylpyridinium (ASP+) HEK293-MATE1 Wittwer, 2013
Sunitinib 0.275 Metformin1,3 HEK293-MATE1 Minematsu, 2011
Tacrine 0.51 1-methyl-4-phenylpyridinium (MPP+) CHO-MATE1 Astorga, 2012
Tacrine 1.1 4-(4-dimethylamino)styryl-N-methylpyridinium (ASP+) HEK293-MATE1 Kido, 2011
Talipexole 66 Tetraethylammonium1 HEK293-MATE1 Tsuda, 2009
Telmisartan 17.9 4-(4-dimethylamino)styryl-N-methylpyridinium (ASP+) HEK293-MATE1 Wittwer, 2013
Tetrabromobisphenol A 23.1 Tetraethylammonium1 HEK293 cells Bruyere, 2017
Tetrabutylammonium 18 Paraquat HEK293 cells Chen, 2007
Tetraethylammonium1 121 Paraquat HEK293 cells Chen, 2007
Tetramethrin 47.5 Tetraethylammonium1 HEK293 cells Chedik, 2017
Tetramethylammonium 5073 Paraquat HEK293 cells Chen, 2007
Tetrapropylammonium 63 Paraquat HEK293 cells Chen, 2007
Topotecan 1.3 4-(4-dimethylamino)styryl-N-methylpyridinium (ASP+) HEK293-MATE1 Wittwer, 2013
Tramadol 17.8 1-methyl-4-phenylpyridinium (MPP+) CHO-MATE1 Astorga, 2012
Trichlormethiazide 249 1-methyl-4-phenylpyridinium (MPP+) CHO-MATE1 Astorga, 2012
Trimethoprim4 9.7 1-methyl-4-phenylpyridinium (MPP+) CHO-MATE1 Astorga, 2012
Trospium 11.6 1-methyl-4-phenylpyridinium (MPP+) HEK293-MATE1 Chen, 2017
Tubocurarine 9.4 4-(4-dimethylamino)styryl-N-methylpyridinium (ASP+) HEK293-MATE1 Wittwer, 2013
Vecuronium bromide 1.9 4-(4-dimethylamino)styryl-N-methylpyridinium (ASP+) HEK293-MATE1 Wittwer, 2013
Verapamil 42 1-methyl-4-phenylpyridinium (MPP+) CHO-MATE1 Astorga, 2012
Verapamil 27.5 Tetraethylammonium1 HEK293-MATE1 Tsuda, 2009
Zafirlukast 1.3 4-(4-dimethylamino)styryl-N-methylpyridinium (ASP+) HEK293-MATE1 Wittwer, 2013

ND = not determined
1 denotes drugs that can potentially be used as in vitro substrates for studies of the transporter as defined by the FDA as of March 2022
2 denotes drugs that can potentially be used as in vitro inhibitors for studies of the transporter as defined by the FDA as of March 2022
3 denotes drugs that can potentially be used as clinical substrates for studies of the transporter as defined by the FDA as of March 2022
4 denotes drugs that can potentially be used as clinical inhibitors for studies of the transporter as defined by the FDA as of March 2022


Back to top

Clinical Drug-Drug Interactions

DDI Implicated Transporter Interacting Drug Affected Drug AUC Cmax CLR CL/F t1/2 Effect on PD Reference More Details
Clinical PK Impact(fold change)
1 OCT2/MATEs Abemaciclib Metformin1,3 1.37 1.22 0.55 ND NS yes Chappell, 2019 DDI 1
2 OCTs/MATEs Cetirizine Pilsicainide 1.4 NS ND ND ND ND Tsuruoka, 2006 DDI 2
3 OCTs/MATEs Cimetidine2,4 Cephalexin NS NS 0.8 0.8 NS ND van, 1986 DDI 3
4 OCTs/MATEs Cimetidine2,4 Dofetilide 1.5 1.3 0.7 0.7 1.3 yes Abel, 2000 DDI 4
5 OCT2/MATE1 Cimetidine2,4 Glycopyrronium 1.22 NS 0.77 Dumitras, 2013 DDI 5
6 OCTs/MATEs Cimetidine2,4 Metformin1,3 1.5 1.7 0.7 ND ND ND Somogyi, 1987 DDI 6
7 OCTs/MATEs Cimetidine2,4 Pilsicainide 1.3 NS 0.7 0.7 1.2 ND Shiga, 2000 DDI 7
8 OCTs/MATEs Cimetidine2,4 Pindolol (S-enantiomer) 1.4 1.3 0.7 ND NS ND Somogyi, 1992 DDI 8
9 OCTs/MATEs Cimetidine2,4 Procainamide 1.4 NS 0.6 ND 1.3 ND Somogyi, 1983 DDI 9
10 OCTs/MATEs Cimetidine2,4 Ranitidine 1.3 NS 0.7 ND 1.3 ND van, 1986 DDI 10
11 OCTs/MATEs Cimetidine2,4 Varenicline 1.3 ND 0.8 0.8 ND ND Feng, 2008 DDI 11
12 OCTs/MATEs Isavuconazole4 Metformin1,3 1.52 1.22 ND 0.66 1.14 ND Yamazaki, 2017 DDI 12
13 OCTs/MATEs Plazomicin Metformin1,3 1.04 1.1 0.99 0.97 0.92 Choi, 2019 DDI 13
14 MATEs Pyrimethamine2 Metformin1,3 1.4 1.4 0.6 ND ND ND Kusuhara, 2011 DDI 14
15 OCTs/MATEs Ranitidine Trospium (IV) 1.06 1.10 0.87 1.1 1.00 No Abebe, 2020 DDI 15
16 OCTs/MATEs Ranitidine Trospium (oral) 0.87 0.92 0.99 NR 0.98 No Abebe, 2020 DDI 16
17 OCTs/MATEs Test cocktail 1: digoxin, furosemide, metformin, and rosuvastatin Metformin1,3 0.99 1.1 Stopfer, 2016 DDI 17
18 OCTs/MATEs Test cocktail 3: digoxin, metformin, rosuvastatin, and increased furosemide Metformin1,3 1.03 1.03 Stopfer, 2016 DDI 18
19 OCT1/MATEs Verapamil Metformin1,3 1.07 1.09 0.98 NR 0.80 Yes Cho, 2014 DDI 19

The transporters are implicated by in vitro data and/or studies in humans with genetic polymorphisms of the transporter
DDI = Drug Drug Interaction
PK = pharmacokinetic
PD = pharmacodynamic
ND = not determined
NS = not significant
N/A = information not available
Calculation of Fold Change: fold change in the presence of the interacting drug = (value with interacting drug)/(value without interacting drug)
fold change > 1: increase in pharmacokinetic value
fold change < 1: decrease in pharmacokinetic value
1 denotes drugs that can potentially be used as in vitro substrates for studies of the transporter as defined by the FDA as of March 2022
2 denotes drugs that can potentially be used as in vitro inhibitors for studies of the transporter as defined by the FDA as of March 2022
3 denotes drugs that can potentially be used as clinical substrates for studies of the transporter as defined by the FDA as of March 2022
4 denotes drugs that can potentially be used as clinical inhibitors for studies of the transporter as defined by the FDA as of March 2022


Back to top

Contact us | Glossary

Blue banner